» Articles » PMID: 30848549

Diagnostic Accuracy of Positron Emission Tomography/Computed Tomography of the Head, Neck, and Chest for Giant Cell Arteritis: A Prospective, Double-Blind, Cross-Sectional Study

Overview
Publisher Wiley
Specialty Rheumatology
Date 2019 Mar 9
PMID 30848549
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Positron emission tomography/computed tomography (PET/CT) has not been well studied as a first-line test for giant cell arteritis (GCA), due, in part, to historical limitations in visualizing the cranial arteries. The Giant Cell Arteritis and PET Scan (GAPS) study was therefore carried out to assess the accuracy of a newer generation PET/CT of the head, neck, and chest for determining a diagnosis of GCA.

Methods: In the GAPS study cohort, 64 patients with newly suspected GCA underwent time-of-flight PET/CT (1-mm slice thickness from the vertex to diaphragm) within 72 hours of starting glucocorticoids and before undergoing temporal artery biopsy (TAB). Two physicians with experience in PET reviewed the patients' scans in a blinded manner and reported the scans as globally positive or negative for GCA. Tracer uptake was graded across 18 artery segments. The clinical diagnosis was confirmed at 6 months' follow-up.

Results: In total, 58 of 64 patients underwent TAB, and 12 (21%) of the biopsies were considered positive for GCA. Twenty-one patients had a clinical diagnosis of GCA. Compared to TAB, the sensitivity of PET/CT for a diagnosis of GCA was 92% (95% confidence interval [95% CI] 62-100%) and specificity was 85% (95% CI 71-94%). The negative predictive value (NPV) was 98% (95% CI 87-100%). Compared to clinical diagnosis, PET/CT had a sensitivity of 71% (95% CI 48-89%) and specificity of 91% (95% CI 78-97%). Interobserver reliability was moderate (κ = 0.65). Among the enrolled patients, 20% had a clinically relevant incidental finding, including 7 with an infection and 5 with a malignancy. Furthermore, 5 (42%) of 12 TAB-positive GCA patients had moderate or marked aortitis.

Conclusion: The high diagnostic accuracy of this PET/CT protocol would support its use as a first-line test for GCA. The NPV of 98% indicates the particular utility of this test in ruling out the condition in patients considered to be at lower risk of GCA. PET/CT had benefit over TAB in detecting vasculitis mimics and aortitis.

Citing Articles

Repeated Cranial and Large-Vessel Positron Emission Tomography/Computed Tomography Scans and the Association With Structural Aortic Disease in Giant Cell Arteritis: A Five-Year Observational Study.

Sammel A, Shon I, Moses D, Fredericks S, Mathur G, Hillenbrand C ACR Open Rheumatol. 2025; 7(3):e70006.

PMID: 40012355 PMC: 11865633. DOI: 10.1002/acr2.70006.


Direct comparison of the diagnostic accuracy of PET/CT, cranial MRI, ultrasound and temporal artery biopsy in giant cell arteritis.

Moreel L, Betrains A, Boeckxstaens L, Pieters G, Wuyts E, Weynand B Eur J Nucl Med Mol Imaging. 2025; .

PMID: 40000462 DOI: 10.1007/s00259-025-07166-6.


Utilising multiple discharge coding will improve identification of patients with giant cell arteritis: a retrospective analysis of a hospital discharge dataset.

Dermawan A, Murdoch J, De Sousa J, Taylor A, Keen H Rheumatol Int. 2025; 45(3):58.

PMID: 39982544 PMC: 11845429. DOI: 10.1007/s00296-025-05814-6.


Comparative analysis of arterial involvement in predominant cranial and isolated extracranial phenotypes of giant cell arteritis using F-FDG PET-CT.

Narvaez J, Vidal-Montal P, Sanchez-Rodriguez I, Sabate-Llobera A, Cortes-Romera M, Palacios-Olid J Arthritis Res Ther. 2024; 26(1):230.

PMID: 39732686 PMC: 11681699. DOI: 10.1186/s13075-024-03464-w.


Clinical Phenotypes of Giant Cell Arteritis: Insights into Complications and Survival Outcomes.

Estrada P, Narvaez J, Moya P, Roig-Vilaseca D, Camacho O, Navarro V Eur J Rheumatol. 2024; 11(2):33-38.

PMID: 39576031 PMC: 11448687. DOI: 10.5152/eurjrheum.2024.23065.